Bromopride


Generic Medicine Info
Indications and Dosage
Oral
Gastrointestinal motility disorders, Nausea and vomiting
Adult: 20-60 mg daily in divided doses.

Parenteral
Gastrointestinal motility disorders, Nausea and vomiting
Adult: IV/IM: 20 mg daily.
Contraindications
GI haemorrhage, obstruction, perforation or immediately after surgery. Patients with pheochromocytoma.
Special Precautions
Children, young patients, elderly; renal impairment, epilepsy, Parkinson's disease; history of depression. May impair ability to drive or operate machinery.
Adverse Reactions
Extrapyramidal symptoms; restlessness, drowsiness, diarrhoea; hypotension, hypertension, dizziness, headache, depression; galactorrhoea.
Potentially Fatal: Neuroleptic malignant syndrome.
Drug Interactions
Other centrally active drugs and those with extrapyramidal effects. Increased toxicity with lithium. Antagonism of GI effects with antimuscarinics and opioid analgesics. May affect absorption of other drugs.
Lab Interference
Transient increase in plasma-aldosterone concentration.
Action
Description:
Mechanism of Action: Bromopride is a substituted benzamide with prokinetic and antiemetic properties.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories
Disclaimer: This information is independently developed by MIMS based on Bromopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in